Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in three upcoming investor conferences in August and September 2025.
The company will participate in: the UBS Precision Medicine Summit with a panel discussion on August 14, the Wells Fargo Healthcare Conference with 1x1 investor meetings on September 4, and the Morgan Stanley Global Healthcare Conference with a fireside chat on September 10. Live and archived webcasts for the UBS and Morgan Stanley events will be available on the company's investor relations website.
Cytek Biosciences (Nasdaq: CTKB), azienda leader nelle soluzioni per l'analisi cellulare, ha annunciato la propria partecipazione a tre conferenze per investitori previste ad agosto e settembre 2025.
L'azienda sarà presente al UBS Precision Medicine Summit con un panel il 14 agosto, al Wells Fargo Healthcare Conference con incontri 1:1 con investitori il 4 settembre e al Morgan Stanley Global Healthcare Conference con un fireside chat il 10 settembre. I webcast in diretta e le registrazioni per gli eventi UBS e Morgan Stanley saranno disponibili sul sito delle relazioni con gli investitori della società.
Cytek Biosciences (Nasdaq: CTKB), empresa líder en soluciones de análisis celular, ha anunciado su participación en tres próximas conferencias para inversores en agosto y septiembre de 2025.
La compañía asistirá al UBS Precision Medicine Summit con una mesa redonda el 14 de agosto, al Wells Fargo Healthcare Conference con reuniones 1:1 con inversores el 4 de septiembre, y al Morgan Stanley Global Healthcare Conference con un fireside chat el 10 de septiembre. Las retransmisiones en directo y las grabaciones de los eventos de UBS y Morgan Stanley estarán disponibles en la web de relaciones con inversores de la compañía.
Cytek Biosciences (Nasdaq: CTKB)는 세포 분석 솔루션 분야의 선도 기업으로, 2025년 8월과 9월에 열리는 세 곳의 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 UBS Precision Medicine Summit에서 8월 14일 패널 토론, Wells Fargo Healthcare Conference에서 9월 4일 일대일 투자자 미팅, 그리고 Morgan Stanley Global Healthcare Conference에서 9월 10일 파이어사이드 채팅에 참여할 예정입니다. UBS와 Morgan Stanley 행사에 대한 생중계 및 녹화 웹캐스트는 회사의 투자자 관계 웹사이트에서 시청할 수 있습니다.
Cytek Biosciences (Nasdaq: CTKB), entreprise de premier plan dans les solutions d'analyse cellulaire, a annoncé sa participation à trois conférences investisseurs prévues en août et septembre 2025.
La société participera au UBS Precision Medicine Summit avec une table ronde le 14 août, au Wells Fargo Healthcare Conference avec des réunions individuelles investisseurs le 4 septembre, et au Morgan Stanley Global Healthcare Conference avec un fireside chat le 10 septembre. Les webdiffusions en direct et les enregistrements des événements UBS et Morgan Stanley seront disponibles sur le site relations investisseurs de la société.
Cytek Biosciences (Nasdaq: CTKB), ein führendes Unternehmen für Zellanalyselösungen, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im August und September 2025 angekündigt.
Das Unternehmen wird am UBS Precision Medicine Summit mit einer Podiumsdiskussion am 14. August teilnehmen, an der Wells Fargo Healthcare Conference mit 1:1-Investorengesprächen am 4. September und an der Morgan Stanley Global Healthcare Conference mit einem Fireside-Chat am 10. September. Live- und Archiv-Webcasts für die Veranstaltungen von UBS und Morgan Stanley sind auf der Investor-Relations-Website des Unternehmens verfügbar.
- None.
- None.
FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.
- UBS Precision Medicine Summit in Dana Point, CA
Panel discussion: New Dimensions in Proteomics and Cellular Research on Thursday, August 14, 2025, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time
- Wells Fargo Healthcare Conference in Boston, MA
Participating in investor 1x1 meetings on Thursday, September 4, 2025
- Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY
Fireside chat on September 10, 2025, at 7:00 a.m. Pacific Time /10:00 a.m. Eastern Time
Interested parties may access live and archived webcasts of the presentations for the UBS and Morgan Stanley events referenced above on the “Investors” section of the company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
FAQ
When is Cytek Biosciences (CTKB) presenting at the Morgan Stanley Healthcare Conference 2025?
Where can I watch Cytek Biosciences' (CTKB) investor conference presentations?
What investor conferences is Cytek Biosciences (CTKB) attending in 2025?
What type of company is Cytek Biosciences (CTKB)?
